Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous CRISPR-Cas9 engineered tumor infiltrating lymphocytes KSQ-001EX

A preparation of autologous tumor infiltrating lymphocytes (TILs) gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to inactivate the endogenous gene suppressor of cytokine signaling 1 (SOCS1), with potential immunomodulating and antineoplastic activities. Upon infusion of the autologous CRISPR-Cas9 engineered TILs KSQ-001EX back into the patient, the cells specifically recognize, target and kill the patient's tumor cells. SOCS1 serves as a negative regulator of cytokine signaling in T cells and negatively influences the survival, differentiation, and function of T cells. Inactivation of endogenous SOCS1 in TILs increases responsiveness to cytokine signals, and enhances anti-tumor potency, persistence and memory formation of TILs.
Synonym:autologous CRISPR-Cas9 engineered TILs KSQ-001EX
autologous engineered tumor infiltrating lymphocytes KSQ-001EX
autologous eTILs KSQ-001EX
autologous SOCS1 inactivated engineered TILs KSQ-001EX
autologous SOCS1-edited TILs KSQ-001EX
CRISPR/Cas9-edited SOCS1 gene-inactivated autologous TILs KSQ-001EX
Code name:KSQ 001EX
KSQ-001EX
KSQ001EX
Search NCI's Drug Dictionary